Use of radionuclides in metastatic prostate cancer: Pain relief and beyond

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 3, 2012, Pages 310-315

  Vengalil, Salil ^a   O'Sullivan, Joe M ^a,b   Parker, Christopher C ^c  

^a Northern Ireland Cancer Centre   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bone metastases; Bone seeking radionuclides; Prostate cancer

Indexed keywords

RADIOISOTOPE; RADIUM; RHENIUM; SAMARIUM; STRONTIUM; STRONTIUM CHLORIDE;

BONE TUMOR; HUMAN; MALE; MEN'S HEALTH; METASTASIS; METHODOLOGY; PAIN; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; REVIEW;

BONE NEOPLASMS; HUMANS; MALE; MEN'S HEALTH; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIUM; RHENIUM; SAMARIUM; STRONTIUM;

EID: 84871253334     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328355e082     Document Type: Review

References (23)

1. Sartor O, Michels RM, Massard C, de Bono JS. Novel therapeutic strategies for metastatic prostate cancer in the postdocetaxel setting. Oncologist 2011; 16:1487-1497.
2. Parker CC. Systemic isotope therapy of bone metastasis. In Horwich A, editor. Systemic treatment of prostate cancer. 1st ed. UK: Oxford Oncology Library; 2010. pp. 65.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
5. Smart JG. Radioactive phosphorus treatment of bone-metastatic carcinoma of the prostate. Lancet 1964; 2:882-883.
6. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
7. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. ASCO Genitourinary Cancers Symposium; 2012.
8. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
9. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25:805-813.
10. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis: a systemic review. Radiother Oncol 2005; 75:258-270.
11. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63:940-945.
12. Han SH, de Klerk JM, Tan S, et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo controlled Rhenium study. J Nucl Med 2002; 43:1150-1156.
13. Roque I, Figuls M, Martinez-Zapata MJ, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011; 7:CD003347.
14. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethyli- denediphosphonate. J Clin Oncol 2003; 21:2869-2875.
15. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336-341.
16. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27:2429-2435.
17. van Dodewaard-de Jong JM, de Klerk JM, Bloemendal HJ, et al. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging 2011; 38:1990-1998.
18. James ND. A randomised phase II/III study of Docetaxel plus prednisolone vs. Docetaxel plus prednisolone plus zoledronic acid vs. Docetaxel plus pre-dnisolone plus Strontium-89 vs. Docetaxel plus prednisolone plus zoledronic acid plus Strontium-89 in hormone refractory prostate cancer metastatic to bone. Available at: http://www.trapeze.bham.ac.uk/.
19. O'Sullivan JM, McCready VR, Flux G, et al. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002; 86:1715-1720.
20. O'Sullivan JM, Norman AR, McCready VR, et al. A phase 2 study of high-Activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging 2006; 33:1055-1061.
21. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594.
22. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011; 47 (Suppl 2):3.
23. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.